Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
1 Beaten-Down Stock With 55% Upside, According to Wall Street
10:30am, Monday, 04'th Mar 2024
Editas Medicine has recorded solid progress with its leading candidate. The biotech's financial position looks strong, given its clinical-stage status.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
09:49pm, Saturday, 02'nd Mar 2024
Editas Medicine's fourth-quarter results contained surprises. Financial results were better than expected.
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
09:46am, Thursday, 29'th Feb 2024
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
04:52pm, Wednesday, 28'th Feb 2024
Results from the Editas Medicine, Inc. phase 1/2 studies using reni-cel for the treatment of patients with Sickle-Cell Disease and Transfusion dependent thalassemia are expected in mid-2024 and end of
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
11:11am, Wednesday, 28'th Feb 2024
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Wednesday, 28'th Feb 2024
Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago.
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
07:00am, Wednesday, 21'st Feb 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade
10:56am, Monday, 19'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 80% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive
5 Biotech Stocks to Consider for Your Portfolio in 2024
10:00am, Tuesday, 13'th Feb 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,
Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)
02:00pm, Wednesday, 07'th Feb 2024
Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)
What Makes Editas (EDIT) a New Buy Stock
01:01pm, Tuesday, 06'th Feb 2024
Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Editas Medicine to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 31'st Jan 2024
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc
2 Under-the-Radar Stocks With Incredible Upside Potential
08:45am, Sunday, 28'th Jan 2024
Editas Medicine's shares could skyrocket as it advances its gene-editing therapies. Recursion Pharmaceuticals is looking to implement a paradigm shift in drug discovery.
Could Editas Medicine Become the Next CRISPR Therapeutics?
09:37am, Sunday, 21'st Jan 2024
Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there.
7 Mighty Healthcare Stocks Changing the Game of Medicine
12:04pm, Wednesday, 17'th Jan 2024
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma
